Unknown

Dataset Information

0

Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy.


ABSTRACT: Anti-CD3 monoclonal antibodies (mAbs) are potent immunosuppressive agents used in clinical transplantation. However, the activation-related adverse side effects associated with these mAbs have prompted the development of less toxic nonmitogenic anti-CD3 mAb therapies. At present, the functional and biochemical consequences of T cell exposure to nonmitogenic anti-CD3 is unclear. In this study, we have examined the early signaling events triggered by a nonmitogenic anti-CD3 mAb. Like the mitogenic anti-CD3 mAb, nonnmitogenic anti-CD3 triggered changes in the T cell receptor (TCR) complex, including zeta chain tyrosine phosphorylation and ZAP-70 association. However, unlike the mitogenic anti-CD3 stimulation, nonmitogenic anti-CD3 was ineffective at inducing the highly phosphorylated form of zeta (p23) and tyrosine phosphorylation of the associated ZAP-70 tyrosine kinase. This proximal signaling deficiency correlated with minimal phospholipase Cgamma-1 phosphorylation and failure to mobilize detectable Ca2+. Not only did biochemical signals delivered by nonmitogenic anti-CD3 resemble altered peptide ligand signaling, but exposure of Th1 clones to nonmitogenic anti-CD3 also resulted in functional anergy. Finally, a bispecific anti-CD3 X anti-CD4 F(ab)'2 reconstituted early signal transduction events and induced proliferation, suggesting that defective association of lck with the TCR complex may underlie the observed signaling differences between the mitogenic and nonmitogenic anti-CD3.

SUBMITTER: Smith JA 

PROVIDER: S-EPMC2196281 | biostudies-literature | 1997 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy.

Smith J A JA   Tso J Y JY   Clark M R MR   Cole M S MS   Bluestone J A JA  

The Journal of experimental medicine 19970401 8


Anti-CD3 monoclonal antibodies (mAbs) are potent immunosuppressive agents used in clinical transplantation. However, the activation-related adverse side effects associated with these mAbs have prompted the development of less toxic nonmitogenic anti-CD3 mAb therapies. At present, the functional and biochemical consequences of T cell exposure to nonmitogenic anti-CD3 is unclear. In this study, we have examined the early signaling events triggered by a nonmitogenic anti-CD3 mAb. Like the mitogenic  ...[more]

Similar Datasets

| S-EPMC3708495 | biostudies-literature
| S-EPMC3907155 | biostudies-literature
| S-EPMC11321054 | biostudies-literature
| S-EPMC6690423 | biostudies-literature
| S-EPMC3924290 | biostudies-literature
2024-05-30 | E-MTAB-13507 | biostudies-arrayexpress
| S-EPMC7545799 | biostudies-literature
| S-EPMC9135708 | biostudies-literature
| S-EPMC6343614 | biostudies-literature
| S-EPMC3338941 | biostudies-literature